Huge acquisition scores Novo Nordisk an FDA-ready treatment

Through acquiring Dicerna, Novo Nordisk is getting its hands on a drug candidate that is expected to be submitted for FDA approval during first quarter of 2022.
by mikkel aabenhus hemmingsen and ulrich quistgaard, translated by catherine brett

In around a year's time, Novo Nordisk may be able to enter a new market with an approved treatment under its belt, after its USD 3.3bn acquisition of Dicerna.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading